Discovery of 3-(1H-benzo[d]imidazole-2-yl)-1H-pyrazol-4 -amine derivatives as novel and potent syk inhibitors for the treatment of hematological malignancies

Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases

(2020) Peter Blomgren et al.   ACS Medicinal Chemistry Letters

Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome

(2020) Radek Jorda et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Recent advance of spleen tyrosine kinase in diseases and drugs

(2020) Yuxin Shao et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Fostamatinib for the treatment of chronic immune thrombocytopenia

(2019) Nathan T. Connell et al.   BLOOD

Resistance mechanisms to SYK inhibition in acute myeloid leukemia

(2019) Anjali Cremer et al.   Cancer Discovery

Fostamatinib: First Global Approval

(2018) Anthony Markham   DRUGS

Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia

(2018) Sushma Bartaula-Brevik et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Recently approved therapies in acute myeloid leukemia: A complex treatment landscape

(2018) Chetasi Talati et al.   LEUKEMIA RESEARCH

Syk inhibitors in clinical development for hematological malignancies

(2017) Delong Liu et al.   Journal of Hematology & Oncology

Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)

(2016) Betty Lam et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Design, synthesis of diaminopyrimidine inhibitors targeting IgE- and IgG-mediated activation of Fc receptor signaling

(2015) Ankush Argade et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery and Profiling of a Selective and Efficacious Syk Inhibitor

(2015) Gebhard Thoma et al.   JOURNAL OF MEDICINAL CHEMISTRY

Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations?

(2014) Matthew C Lucas et al.   Future Medicinal Chemistry

Using Ovality to Predict Nonmutagenic, Orally Efficacious Pyridazine Amides as Cell Specific Spleen Tyrosine Kinase Inhibitors

(2014) Matthew C. Lucas et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase

(2014) Kevin S. Currie et al.   JOURNAL OF MEDICINAL CHEMISTRY

Getting Syk: spleen tyrosine kinase as a therapeutic target

(2014) Robert L. Geahlen   TRENDS IN PHARMACOLOGICAL SCIENCES

Pyrrolopyrazines as Selective Spleen Tyrosine Kinase Inhibitors

(2013) Fernando Padilla et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting the SYK–BTK axis for the treatment of immunological and hematological disorders

(2013) Seng-Lai Tan et al.   PHARMACOLOGY & THERAPEUTICS

The Syk kinase as a therapeutic target in leukemia and lymphoma

(2011) Dimitar G Efremov et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Spleen tyrosine kinases: biology, therapeutic targets and drugs

(2010) Mauro Riccaboni et al.   DRUG DISCOVERY TODAY

Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France)

(2010) M. Maynadie et al.   HAEMATOLOGICA

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis

(2010) Michael E. Weinblatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Autoinhibition and adapter function of Syk

(2009) Yogesh Kulathu et al.   IMMUNOLOGICAL REVIEWS

The tyrosine kinase network regulating mast cell activation

(2009) Alasdair M. Gilfillan et al.   IMMUNOLOGICAL REVIEWS